Nascent biotechnology firm Solidus Biosciences is developing a cell-based assay chip that it says can perform rapid and inexpensive assessment of ADME/tox early on in the drug-development process, thereby eliminating unsuitable small-molecule candidates from further investigation.

The technology, which has been dubbed MetaChip, combines an array of sol-gel encapsulated cytochrome P450 metabolizing enzymes with a monolayer of cells on a micro-scale glass slide that can be read using any standard microarray scanner, fluorescent microscope, or combination thereof.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.